FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

product portfolio News

Most Popular product portfolio Story

CombinatoRx dumps RA program as data fails to add up

CombinatoRx has opted to abandon a development program for its rheumatoid arthritis therapy, CRx-150, after the latest set of trial data failed to demonstrate the kind of effectiveness needed to compete for that market. Researchers said that the therapy did demonstrate statistically significant responses for two key criteria in the trial, but failed to perform in a third.

"The level of activity observed with CRx-150 would not be competitive within the CombinatoRx product portfolio …

... Read more...

Latest Headlines